Big name companies continue to be the focus of interest for investors keen to lift exposure to secular trends like artificial intelligence and anti-obesity drugs. The absence of near-term competition and lack of clarity on how these technologies will develop in the longer term means investors continue to pile into a handful of companies.
Investment